Question 1

How does ID Pharma (Japan) rank in research?

Accepted Answer

ID Pharma (Japan) ranks #34,221 of 34,923 institutions worldwide on research quality over all time, and #1,829 of 1,923 in Japan.

Question 2

Who are the top researchers at ID Pharma (Japan)?

Accepted Answer

Ranked on the quality score, Noemi Fusaki, Mamoru Hasegawa and Akihiro Iida lead among researchers whose main affiliation is ID Pharma (Japan).

Question 3

What are the most cited papers from ID Pharma (Japan)?

Accepted Answer

The most cited paper from ID Pharma (Japan) is "Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome" (Noemi Fusaki, Hiroshi Ban, Akiyo Nishiyama et al., 2009), with 1,416 citations. Next come "Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging" (786) and "Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells" (646).

Question 4

Which research topics does ID Pharma (Japan) publish most on?

Accepted Answer

By volume in 2022-now: CRISPR and Genetic Engineering, Pluripotent Stem Cells Research, Immune Cell Function and Interaction and Animal Genetics and Reproduction.

Question 5

Which keywords describe research at ID Pharma (Japan)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Gene Therapy, Genomic Integration, AAV, Viral Vectors, Vaccine, Epidemiology, Pathogenesis and Immune Response.

Question 6

Which fields of science does ID Pharma (Japan) work in?

Accepted Answer

In all years, 57% of research at ID Pharma (Japan) is in Life Sciences, 31% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (41%), Medicine (31%), Immunology and Microbiology (8%). It does 3.5× the world's share of Life Sciences.

Question 7

Is ID Pharma (Japan)'s research output growing?

Accepted Answer

Output in 2022-2025 was 23% lower than in 2018-2021.